Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A ctDNA Screening Program in Patients With HR+, HER2 Low Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor Followed by a Single Arm Phase II Trial of Trastuzumab-deruxtecan in Patients With Persistent ctDNA After 1 Month of Treatment With Endocrine Therapy Combined With CDK4/6 Inhibitor

NCT06680596 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT06680596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06680596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A ctDNA Screening Program in Patients With HR+, HER2 Low Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor Followed by a Single Arm Phase II Trial of Trastuzumab-deruxtecan in Patients With Persistent ctDNA After 1 Month of Treatment With Endocrine Therapy Combined With CDK4/6 Inhibitor
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
July 30, 2025
Completion date
August 1, 2029
Enrollment
80 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic, breast cancer stage iv